CGEN's logo.
Ticker Symbol: CGEN

Compugen Ltd

$5.16 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001119774

Company Profile

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is expected to enter the clinic in early 2020. The Company's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA.

Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: N/A
Website: www.cgen.com
CEO: N/A
Tags:
  • Health Technology
  • Biotechnology

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $0.72
Change: -$0.01 ( -2.57%)
Days Range: $0.70 - $0.75
Beta: 1.89
52wk. High: $1.49
52wk. Low: $0.55
Ytd. Change 0.83%
50 Day Moving Average: $0.95
200 Day Moving Average: $0.97
Shares Outstanding: 88233766

Valuation

Market Cap: 6.4B
PE Ratio: -1.83
EPS (TTM): -0.3933

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A